Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2326-2332

  Brown, Kevin A ^a   Khanafer, Nagham ^b   Daneman, Nick ^c   Fisman, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; MACROLIDE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM;

ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY; DISEASE ASSOCIATION; DRUG EXPOSURE; HUMAN; INCIDENCE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; DATABASES, BIBLIOGRAPHIC; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84876236060     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02176-12     Document Type: Article

References (36)

1. Kwong J, Crowcroft N, Campitelli M, Daneman N, Deeks S, Manuel D. 2010. Ontario Burden of Infectious Disease Study (ONBOIDS): an OAHPP/ICES report. Ontario Agency for Health Protection and Promotion and Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
2. Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, Fraser VJ. 2007. Evaluation of Clostridium difficileassociated disease pressure as a risk factor for C. difficile-associated disease. Arch. Intern. Med. 167:1092-1097.
3. Centers for Disease Control and Prevention. 2005. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. Morb. Mortal. Wkly. Rep. 54:1201-1205.
4. Bauer MP, Veenendaal D, Verhoef L, Bloembergen P, Van Dissel JT, Kuijper EJ. 2009. Clinical and microbiological characteristics of community- onset Clostridium difficile infection in The Netherlands. Clin. Microbiol. Infect. 15:1087-1092.
5. Rangaiah J, Wilks M, Millar M. 2009. Community Clostridium difficile. BMJ 338:b1346. doi:10.1136/bmj.b2195.
6. Al Saif N, Brazier J. 1996. The distribution of Clostridium difficile in the environment of South Wales. J. Med. Microbiol. 45:133-137.
7. Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. 2007. Clostridium difficile in retail ground meat, Canada. Emerg. Infect. Dis. 13: 485-487.
8. Miyajima F, Roberts P, Swale A, Price V, Jones M, Horan M, Beeching N, Brazier J, Parry C, Pendleton N, Pirmohamed M. 2011. Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One 6:e22804. doi:10.1371/journal.pone.0022804.
9. Kuntz J, Chrischilles E, Pendergast J, Herwaldt L, Polgreen P. 2011. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect. Dis. 11:194. doi: 10.1186/1471-2334-11-194.
10. Bignardi GE. 1998. Risk factors for Clostridium difficile infection. J. Hosp. Infect. 40:1-15.
11. Thomas C, Stevenson M, Riley TV. 2003. Antibiotics and hospitalacquired Clostridium difficile-associated diarrhoea: a systematic review. J. Antimicrob. Chemother. 51:1339-1350.
12. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, Tharyan P, Colford JM. 2004. Systematic reviews and meta-analyses: an illustrated, step-by-step guide. Natl. Med. J. India 17:86-95.
13. Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. 2007. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch. Intern. Med. 167:1393-1399.
14. Sanderson S, Tatt ID, Higgins JP. 2007. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int. J. Epidemiol. 36:666-676.
15. Downs SH, Black N. 1998. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J. Epidemiol. Community Health 52:377-384.
16. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, STROBE Initiative. 2007. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 4:e297. doi:10.1371 /journal.pmed. 0040297.
17. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. 2008. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 179:767-772.
18. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin. Trials 7:177-188.
19. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. 1994. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J. Infect. Dis. 169:127-133.
20. Levy DG, Stergachis A, McFarland LV, Van Vorst K, Graham DJ, Johnson ES, Park BJ, Shatin D, Clouse JC, Elmer GW. 2000. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin. Ther. 22:91-102.
21. Agresti A. 1999. On logit confidence intervals for the odds ratio with small samples. Biometrics 55:597-602.
22. Davies HTO, Crombie IK, Tavakoli M. 1998. When can odds ratios mislead? BMJ 316:989-991.
23. Higgins JPT, Thompson SG. 2002. Quantifying heterogeneity in a metaanalysis. Stat. Med. 21:1539-1558.
24. Smith G, Egger M. 2001. Going beyond the grand mean: subgroup analysis in meta-analysis of randomised trials, p 143-156. In Systematic review in health care: meta-analysis in context. BMJ Publishing Group, London, England.
25. Viechtbauer W. 2010. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36:1-48.
26. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. 2006. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin. Infect. Dis. 43:1272-1276.
27. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. 2008. A case-control study of community-associated Clostridium difficile infection. J. Antimicrob. Chemother. 62:388-396.
28. Stevens V, Dumyati G, Fine LS, Fisher SG, Van Wijngaarden E. 2011. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis. 53:42-48.
29. Aspevall O, Lundberg A, Burman LG, Åkerlund T, Svenungsson B. 2006. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob. Agents Chemother. 50:1890-1892.
30. Owens RC, Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46:S19-S31.
31. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. 2006. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob. Agents Chemother. 50:3216-3219.
32. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719.
33. Egger M, Schneider M, Smith GD. 1998. Meta-analysis spurious precision? Meta-analysis of observational studies. BMJ 316:140-144.
34. Delaney JAC, Dial S, Barkun A, Suissa S. 2007. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg. Infect. Dis. 13:761-763.
35. Pultz NJ, Donskey CJ. 2005. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob. Agents Chemother. 49:3529-3532.
36. Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, Kutty PK, McDonald LC, Woods CW. 2011. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am. J. Med. 124:276.e1-276.e7.